These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 29407591

  • 21. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
    Depoortère R, Auclair AL, Bardin L, Bruins Slot L, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A.
    Br J Pharmacol; 2007 May; 151(2):266-77. PubMed ID: 17375085
    [Abstract] [Full Text] [Related]

  • 22. (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.
    TenBrink RE, Bergh CL, Duncan JN, Harris DW, Huff RM, Lahti RA, Lawson CF, Lutzke BS, Martin IJ, Rees SA, Schlachter SK, Sih JC, Smith MW.
    J Med Chem; 1996 Jun 21; 39(13):2435-7. PubMed ID: 8691438
    [No Abstract] [Full Text] [Related]

  • 23. N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT(7) receptor selectivity versus multireceptor profile.
    Canale V, Kurczab R, Partyka A, Satała G, Słoczyńska K, Kos T, Jastrzębska-Więsek M, Siwek A, Pękala E, Bojarski AJ, Wesołowska A, Popik P, Zajdel P.
    Bioorg Med Chem; 2016 Jan 15; 24(2):130-9. PubMed ID: 26706111
    [Abstract] [Full Text] [Related]

  • 24. 6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
    Favor DA, Powers JJ, White AD, Fitzgerald LW, Groppi V, Serpa KA.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5666-9. PubMed ID: 20801650
    [Abstract] [Full Text] [Related]

  • 25. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
    Liégeois JF, Deville M, Dilly S, Lamy C, Mangin F, Résimont M, Tarazi FI.
    J Med Chem; 2012 Feb 23; 55(4):1572-82. PubMed ID: 22268448
    [Abstract] [Full Text] [Related]

  • 26. Discovery of aryl-piperidine derivatives as potential antipsychotic agents using molecular hybridization strategy.
    Zhu C, Li X, Zhao B, Peng W, Li W, Fu W.
    Eur J Med Chem; 2020 May 01; 193():112214. PubMed ID: 32182489
    [Abstract] [Full Text] [Related]

  • 27. Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
    Gao L, Hao C, Chen J, Ma R, Zheng L, Wu Q, Liu X, Liu BF, Zhang G, Chen Y, Jin J.
    Bioorg Med Chem Lett; 2021 May 15; 40():127909. PubMed ID: 33705900
    [Abstract] [Full Text] [Related]

  • 28. Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
    Cao X, Zhang Y, Chen Y, Qiu Y, Yu M, Xu X, Liu X, Liu BF, Zhang L, Zhang G.
    J Med Chem; 2018 Nov 21; 61(22):10017-10039. PubMed ID: 30383372
    [Abstract] [Full Text] [Related]

  • 29. Synthesis and evaluation of a series of piperidine-2,6-dione-piperazine (piperidine) derivatives as multireceptor atypical antipsychotics.
    Chen Y, Xu X, Liu X, Liu BF, Zhang G.
    Arch Pharm (Weinheim); 2012 Nov 21; 345(11):859-69. PubMed ID: 22886598
    [Abstract] [Full Text] [Related]

  • 30. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P, Newman-Tancredi A, Loock T, Cussac D.
    Eur J Pharmacol; 2008 Feb 26; 581(1-2):37-46. PubMed ID: 18190908
    [Abstract] [Full Text] [Related]

  • 31. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
    Kołaczkowski M, Marcinkowska M, Bucki A, Śniecikowska J, Pawłowski M, Kazek G, Siwek A, Jastrzębska-Więsek M, Partyka A, Wasik A, Wesołowska A, Mierzejewski P, Bienkowski P.
    Eur J Med Chem; 2015 Mar 06; 92():221-35. PubMed ID: 25557493
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y, Horiguchi M, Rajagopal L, Miyauchi M, Meltzer HY.
    Behav Brain Res; 2015 May 15; 285():165-75. PubMed ID: 25448429
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M.
    J Pharmacol Exp Ther; 2010 Jul 15; 334(1):171-81. PubMed ID: 20404009
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.